Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 mai 2019 17h01 HE | Source: Cybrexa Therapeutics

Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy

Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP...
02 avr. 2019 08h00 HE | Source: Cybrexa Therapeutics

Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity

Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors Poster presentation today during AACR Annual Meeting 2019 ...